|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis - Interleukin-6 (IL-6) and Receptor (IL-6R) Antagonists
La Merie, Nov 2010, Pages: 20
Interleukin-6 (IL-6) and Receptor (IL-6R) Antagonists 2010
The present Competitive Intelligence Report about Interleukin-6 (IL-6) and Receptor (IL-6R) Antagonists for treatment of rheumatoid arthritis and multiple myeloma provides a competitor evaluation in the field of R&D projects with Interleukin-6 (IL-6) and Receptor (IL-6R) Antagonists as of November 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Although the causes of rheumatoid arthritis are not fully understood, constitutive overproduction of interleukin-6 (IL-6), a multifunctional cytokine that regulates immune response, inflammatory reaction and bone metabolism, is thought to play a major pathological role in RA. With the recent approval of tocilizumab, a humanized anti-IL-6 receptor antibody originating from Chugai and under development at Roche in Western countries, this target has become clinically validated and now can show its commercial potential in competition with TNF blockers.
The report includes a compilation of currently active projects in research and development of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) antagonists. In addition, the report lists company-specific R&D pipelines of IL-6/R antagonists. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category/Therapeutic Area,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index:
- IL-6 and IL-6R Antagonists in Inflammation
- IL-6 and IL-6R Antagonists in Oncology
- Small Molecule Approaches of IL-6 and IL-6R Antagonists
Customers who bought this item also bought
Competitor Analysis - Interleukin-1 (IL-1) and Receptor (IL-1R) Antagonists
Competitor Analysis: Emerging Diabetes Drugs
Competitor Analysis - Antibody Therapy of Inflammatory and Autoimmune Diseases
Competitor Analysis - Cancer Antibodies in Early Clinical Development
Pharmaceutical Industry Dynamics 2010: Licensing Opportunities: Rheumatology
Biologics Pipelines: Who Has the Next Promising Monoclonal Antibodies?
Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists
Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging Technologies and New Therapeutic Candidates
Dealmaking and Industry Outlook: Autoimmune and Inflammatory Diseases
The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others
|
|
|
|
